Lipur (Gemfibrozil)

Gemfibrozil acts on lipid metabolism disorders, helping to normalize triglyceride and cholesterol levels.

• Hypertriglyceridemia: reduces serum triglyceride concentrations.
• Mixed dyslipidemia: improves overall lipid profile by lowering triglycerides and modestly raising HDL‑cholesterol.
• Prevention of pancreatitis associated with severe hypertriglyceridaemia: lowers the risk of pancreatitis by controlling extreme triglyceride elevations.

• Gemfibrozil activates peroxisome proliferator‑activated receptor alpha (PPARα), which increases the synthesis of lipoprotein lipase and enhances the catabolism of triglyceride‑rich lipoproteins. It also suppresses hepatic very‑low‑density lipoprotein (VLDL) production, leading to reduced circulating triglycerides and modest changes in other lipid fractions.

Gemfibrozil may cause a range of adverse reactions, from mild gastrointestinal discomfort to rare but serious systemic events.

Common Side Effects

• Dyspepsia: upset stomach or indigestion.
• Nausea: feeling of queasiness.
• Diarrhea: loose, frequent stools.
• Abdominal pain: cramping or discomfort in the stomach area.

Serious or Rare Side Effects

• Myopathy: muscle weakness or pain.
• Rhabdomyolysis: severe muscle breakdown that can affect kidney function.
• Hepatotoxicity: liver enzyme elevations or liver injury.

Before initiating therapy, clinicians should evaluate several safety considerations.

• Liver function monitoring: assess hepatic enzymes periodically.
• Renal function assessment: adjust use in patients with impaired kidney function.
• Statin co‑administration: avoid high‑dose statins due to increased myopathy risk.
• Patient education: advise patients to report unexplained muscle pain or weakness promptly.
• Contraindication in severe hepatic impairment: do not use in patients with active liver disease.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Gemfibrozil interacts with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Statins (especially high‑dose): markedly increased risk of myopathy and rhabdomyolysis.
• Cyclosporine: elevated gemfibrozil plasma concentrations.
• Warfarin: enhanced anticoagulant effect, raising bleeding risk.
• Bile‑acid sequestrants: reduced absorption of gemfibrozil, diminishing efficacy.

Moderate Interactions (Monitor Closely)

• Oral hypoglycemics: potential augmentation of hypoglycaemic effect.
• Other fibrates: additive toxicity, particularly muscle‑related.
• Certain antibiotics (e.g., erythromycin): possible pharmacokinetic interaction affecting drug levels.